EpiPredict SIGNED
Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0EpiPredict project word cloud
Explore the words cloud of the EpiPredict project. It provides you a very rough idea of what is the project "EpiPredict" about.
Project "EpiPredict" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT VAN AMSTERDAM
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Project website | http://redict.eu |
| Total cost | 2˙797˙697 € |
| EC max contribution | 2˙797˙697 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2014 |
| Funding Scheme | MSCA-ITN-ETN |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-01-01 to 2018-12-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. The EpiPredict intersectorial training programme employs a timely systems medicine approach combining next-generation systematic epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference technologies for iterative computational modelling. Together the ESRs will identify key epigenetic changes underlying Tamoxifen induced resistance. This will provide an important step towards diagnostic markers/tools to predict treatment outcome and response monitoring setting the scene for breast cancer personalized medicine. The fellows will be trained by experts from 6 academic and 2 non-academic beneficiaries and 7 partner organizations (1 academic, 6 non-academic including industrial/socio-public parties) and 5 visiting scientists, from fields ranging from epigenetics to both computation and medicine. Strong involvement of the private sector ensures exploitation of EpiPredict achievements and exposure of the ESRs to an entrepreneurial mindset. The cohort of supradisciplinary researchers represents a new generation of research leaders equipped to address complex diseases whilst taking personalized patient aspects into consideration. They will be equipped to compete successfully and succeed in their personal careers. EpiPredict will boost academia and pharma/biotech environments, providing extra impulses to drive European translational science, systems medicine, pharmaceutical industry, and Medical ICT offering ample job opportunities.
Deliverables
| Prizes second annual meeting | Other | 2019-07-10 14:48:58 |
| PhD degrees | Other | 2019-07-10 14:48:58 |
| Prizes fourth annual meeting | Other | 2019-07-10 14:48:58 |
| Prizes third annual meeting | Other | 2019-07-10 14:48:58 |
| Prize first annual meeting | Other | 2019-07-10 14:48:57 |
Take a look to the deliverables list in detail: detailed list of EpiPredict deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Özge Saatci, Simone Borgoni, Özge Akbulut, Selvi Durmuş, Umar Raza, Erol Eyüpoğlu, Can Alkan, Aytekin Akyol, Özgür Kütük, Stefan Wiemann, Özgür Şahin Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer published pages: 2251-2269, ISSN: 0950-9232, DOI: 10.1038/s41388-017-0108-9 |
Oncogene 37/17 | 2019-07-10 |
| 2017 |
D Goubert, W F Beckman, P J Verschure, M G Rots Epigenetic editing: towards realization of the curable genome concept published pages: 13006, ISSN: 2057-1739, DOI: 10.1088/2057-1739/aa5cc0 |
Convergent Science Physical Oncology 3/1 | 2019-07-10 |
| 2018 |
Thierry D.G.A. Mondeel, Stefania Astrologo, Yanfei Zhang, Hans V. Westerhoff NET works after all? Engineering robustness through diversity published pages: 128-137, ISSN: 2405-8963, DOI: 10.1016/j.ifacol.2018.09.007 |
IFAC-PapersOnLine 51/19 | 2019-07-10 |
| 2016 |
Juan Song, David Cano Rodriguez, Melanie Winkle, Rutger A.F. Gjaltema, Désirée Goubert, Tomasz P. Jurkowski, Irene H Heijink, Marianne G. Rots, Machteld N Hylkema Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells published pages: ajplung.00059.20, ISSN: 1040-0605, DOI: 10.1152/ajplung.00059.2016 |
American Journal of Physiology - Lung Cellular and Molecular Physiology | 2019-07-10 |
| 2017 |
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J Verschure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer published pages: 444-450, ISSN: 1061-4036, DOI: 10.1038/ng.3773 |
Nature Genetics 49/3 | 2019-07-10 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIPREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EPIPREDICT" are provided by the European Opendata Portal: CORDIS opendata.